Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EGFR mutation

- PMLiVE

Amgen enters into $540m immunotherapy collaboration

Acquires global rights to Advaxis’ preclinical oncology candidate ADXS-NEO

- PMLiVE

Keytruda cleared in Europe for lung cancer

New second-line indication for Merck’s drug puts it in direct competition with BMS’ Opdivo

- PMLiVE

Boehringer starts to feel impact of Spiriva generics

Asthma and COPD therapy facing increasing competition in ‘crowded’ market category

- PMLiVE

AZ feels Crestor sting but new products provide some relief

Tagrisso and Lynparza boost sales while a string of new cancer studies are in the pipeline

Brextinction

Evolution predicts tragic consequences from the UK's choice

- PMLiVE

Evolve or die

How brand teams can bring more value to their customers

Boehringer Ingelheim headquarters

Boehringer stops Gilotrif head and neck cancer trials

Trial data suggests the drug is “highly unlikely” to prolong patients’ remission

- PMLiVE

EU clears AZ’s FDA-rejected diabetes combination

Approval of two-drug therapy Qtern presents first-to-market advantage in Europe

Deal Watch June 2016

Allergan, Novartis and Merck & Co are among those featured in this month's round-up of pharma deal activity

Bristol-Myers Squibb (BMS) building

SMC gives green light for BMS’ Opdivo

Scotland will be first UK country to access the drug after NICE refusal

- PMLiVE

Pfizer set to snap up Bind’s assets for $20m

Biotech approves 'stalking horse' bid from the pharma giant

- PMLiVE

LEO Pharma picks up AZ skin disease drugs in $1bn deal

Gains rights to eczema and psoriasis treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links